Measure your patient’s immune response to lung cancer
VeriStrat results within 72 hours are predictive of outcomes, independent of ECOG performance status, PD-L1 expression, mutation status, and treatment choice
Results are predictive of outcomes, independent of treatment choice, PD-L1 expression, and mutation status
• Carbone et al. 2012 (BR.21) Image Source: Carbone et al. 2012 (BR.21)
• Grossi et al. 2018 (NEXUS) • Grossi et al. 2017 (BJC) • Gregorc et al. 2014 (PROSE) • Stinchcombe et al. 2013 Image Source: Grossi et al. 117(2018):64-69
• Fidler et al. 2018 (RUSH) • Gadgeel et al. 2017 (LL8) • Gregorc et al. 2014 (PROSE) • Carbone et al. 2012 (BR.21) • Amann et al. 2010 • Taguchi et al. 2007 Image Source: Scagliotti et al. 2018 (MARQUEE)
• Grossi et al. J Thorac Oncol.2017; 12 (S1322 P3.02c-074) Biodesix, data on file Image Source: Rich P, et al 2019 (Multidisciplinary Thoracic Cancers Symposium poster)
ROBUST, BLOOD-BASED TEST VALIDATED ACROSS 70+ STUDIES WITH OVER 6,600 PATIENTSSEE DATA
There are two sides to a VeriStrat test result
VeriStrat identifies a chronic inflammatory disease state associated with aggressive cancer. VeriStrat classifies patients as:
- VeriStrat Good: more likely to benefit from standard of care treatments
- VeriStrat Poor: may benefit from an alternative treatment strategy
DOWNLOAD VERISTRAT POOR REPORT Image Source: Grossi et al. 2017 (NEXUS Study)
Have the conversation
- Novel combination therapies
- NGS testing for rare mutations
- Non-platinum based regimen
- Palliative Care
Source: Data on file – Biodesix 2018
Patients prefer to understand their cancer prognosis and expected outcome
- Improved disease knowledge results in better quality care and quality of life for both the patient and caregiver.¹ ²
- Over 95% of patients want to know their prognosis.³
- Providing detailed information on prognosis decreases patient anxiety.
- Clinical guidelines encourage clear communication of prognosis with patients, caregivers and their families on an ongoing basis.
Reference: 1 Wright et al. Jama 300, no. 14 (2008): 1665-1673 2 Sullivan et al. Journal of palliative medicine 10, no. 4 (2007): 882-893. 3 Hagerty et al. Journal of clinical oncology 22, no. 9 (2004): 1721-1730.
“It is recommended that all physicians caring for patients with lung cancer should begin conversations about the patient’s prognosis and goals of care at the time of the diagnosis, and continue these throughout the course of the illness.”
Reprinted from CHEST, 143 /5(Suppl), Detterbeck et al., Executive Summary Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines / Palliative and End-of-Life Care in Lung Cancer, Page No. 37S, Copyright (2013), with permission from Elsevier.